Anixa Biosciences ROE 2024

Anixa Biosciences Aktienanalyse

What does Anixa Biosciences do?

Anixa Biosciences Inc is a biotechnology company focused on the development and commercialization of cancer therapeutics. The company is headquartered in San Jose, California and was founded in 1982. The history of Anixa Biosciences Inc began as a subsidiary of VaxGen Inc, a now dissolved biotechnology company. Originally, Anixa focused on the development of vaccines for infectious diseases before shifting its focus to cancer therapeutics. Since 2016, Anixa Biosciences Inc has made rapid progress, particularly in the field of cancer immunotherapy. The company has formed several partnerships with other major pharmaceutical companies such as Cleveland Clinic and OntoChem to accelerate the development of treatments for various types of cancer. Anixa Biosciences Inc's business model is based on the development and commercialization of patented cancer therapeutics. Anixa has specialized in the development of immunotherapeutics based on its own proprietary technology platform. The company has specialized in three areas: cancer detection, immunotherapy, and antibody production. In cancer detection, the company is working on the development of diagnostic tools that enable doctors to detect and treat cancer at an early stage. In the field of immunotherapy, Anixa has developed various therapeutics that stimulate the body's immune system to attack and destroy cancer cells. The company has specifically developed immunotherapeutics that specialize in targeted attacks on cancer cells. In antibody production, Anixa focuses on the development of monoclonal antibodies that specifically target tumor cells. These antibodies can be used to identify and isolate cancer cells. Additionally, they can be used as carriers for drugs to provide targeted therapies against tumor cells. Another product of Anixa Biosciences Inc is the CchekTM blood test, which was developed for the detection of breast, ovarian, and prostate cancer. The blood test is based on the discovery of specific biomarkers that can indicate an increased presence of cancer cells in blood samples. In 2019, Anixa announced its entry into the rapidly growing market for in-vitro diagnostics. This market includes the development and commercialization of diagnostic tools used for disease identification and monitoring disease progression. Anixa plans to expand its expertise in cancer diagnostics to other disease areas such as cardiovascular diseases and neurological diseases. Overall, Anixa Biosciences Inc has a diverse portfolio of products specializing in the development of cancer therapeutics, diagnostic tools, and immune competence. The company works closely with established research and development companies to enhance its technologies and create new products. Anixa positions itself as an innovative and future-oriented company in the biotechnology industry. Anixa Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Anixa Biosciences's Return on Equity (ROE)

Anixa Biosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Anixa Biosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Anixa Biosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Anixa Biosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Anixa Biosciences Stock

What is the ROE (Return on Equity) of Anixa Biosciences this year?

The ROE of Anixa Biosciences this year is -0.4 undefined.

How has the Return on Equity (ROE) of Anixa Biosciences developed compared to the previous year?

The ROE of Anixa Biosciences has increased by -13.89% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Anixa Biosciences?

A high ROE indicates that Anixa Biosciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Anixa Biosciences?

A low ROE can indicate that Anixa Biosciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Anixa Biosciences affect the company?

A change in ROE (Return on Equity) of Anixa Biosciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Anixa Biosciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Anixa Biosciences?

Some factors that can influence Anixa Biosciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Anixa Biosciences pay?

Over the past 12 months, Anixa Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anixa Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Anixa Biosciences?

The current dividend yield of Anixa Biosciences is .

When does Anixa Biosciences pay dividends?

Anixa Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anixa Biosciences?

Anixa Biosciences paid dividends every year for the past 0 years.

What is the dividend of Anixa Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anixa Biosciences located?

Anixa Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anixa Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anixa Biosciences from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Anixa Biosciences pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Anixa Biosciences in the year 2023?

In the year 2023, Anixa Biosciences distributed 0 USD as dividends.

In which currency does Anixa Biosciences pay out the dividend?

The dividends of Anixa Biosciences are distributed in USD.